An investigation on behalf of investors in Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares over potential wrongdoing at Catalyst Pharmaceutical Partners was announced and NASDAQ:CPRX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/08/2016 -- An investigation for shareholders in Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) was announced over potential breaches of fiduciary duties by certain directors at Catalyst Pharmaceutical Partners.
Investors who purchased shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Catalyst Pharmaceutical Partners directors breached their fiduciary duties.
On February 17, 2016, Catalyst Pharmaceutical Partners, Inc disclosed that it has received a "Refusal To File" letter from the U.S. Food and Drug Administration (FDA) in relation to Firdapse (amifampridine phosphate), its New Drug Application. The "Refusal to File" letter explains that following December 2015 submission and the initial review, the FDA has found that the application was not adequately complete and needs additional supporting information. The letter does not note the acceptability of the clinical data and does not discuss the efficacy or safety of Firdapse. Shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) declined to as low as $0.93 per share on February 17, 2016.
On March 4, 2016, NASDAQ:CPRX shares closed at $1.14 per share.
Those who purchased shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com